Days af­ter In­di­v­ior launch­es au­tho­rized Sub­ox­one gener­ic, My­lan of­fers its copy­cat; In crowd­ed CGRP mar­ket, Alder sub­mits BLA

→ Af­ter a pro­tract­ed court bat­tle in the Unit­ed States to thwart gener­ic com­pe­ti­tion of its block­buster opi­oid ad­dic­tion treat­ment Sub­ox­one ul­ti­mate­ly proved in vain, UK’s In­di­v­ior de­cid­ed to get ahead of the curve on Tues­day, an­nounc­ing that it was launch­ing its own cut-price ver­sion of the drug. On Fri­day, My­lan $MYL launched its copy­cat. It re­mains to be seen which gener­ic will be cheap­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER